Biopharmaceutical Industry
Reducing Uncertainty in PHM by Accounting for Human Factors â " A Case Study in the Biopharmaceutical Industry
... The ultimate goal of prognostics within Through-life Engineering Services (TES) is to accurately predict the remaining useful life (RUL) of components. Prognostic frameworks inherently presume that there is ...
6
Technological knowledge base, R&D organization structure and alliance formation: Evidence from the biopharmaceutical industry
... the biopharmaceutical industry, the knowledge about a few particular technological disciplines or disease areas); but the “architectural knowledge” (the knowledge of how to incorporate the multi-disciplines ...
38
Competitiveness Analysis for China’s Biopharmaceutical Industry based on Porter Diamond Model
... China’s biopharmaceutical industry is an approach to measure the capability of biopharmaceutical products, the capability of occupying the international market shares and the ability to obtain ...of ...
9
One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry
... the biopharmaceutical industry to construct a model where two firms can choose to outsource R&D to an external unit, and/or engage in in- ternal R&D, before competing in a final ...of ...
63
Network Positions and the Probability of Being Acquired: An Empirical Analysis in the Biopharmaceutical Industry
... This article examines the relationship between the firm's direct ties, its inter-firm network prominence and its likelihood of being acquired. We argue that a firm’s direct ties and prominence enhance the firm’s ...
35
Network embeddedness and new product development in the biopharmaceutical industry: The moderating role of open innovation flow
... high-tech industry, the SC literature disregards the effect of firm’s network positions on the likelihood to develop new products (Deeds and Hill, 1996; Rothaermel and Deeds, 2004; Kalaignanam et ...
45
Technological knowledge base, R&D organization structure and alliance formation: Evidence from the biopharmaceutical industry
... Permanent repository link: http://openaccess.city.ac.uk/14000/ Link to published version: http://dx.doi.org/10.1016/j.respol.2007.02.015 Copyright and reuse: City Research Online aims to[r] ...
6
SCP Analysis of Biopharmaceutical Industry in China
... pharmaceutical industry took a decreasing proportion during 2005-2006 and showed an increasing trend, but the increase level in 2010 equal to the increase level in ...
8
On valuing biopharmaceutical product pipelines: an effectuation model and evidence
... underinvestment and performance, we evaluated the integration of traditional DCF with an effectuation model of analysis. Unlike traditional financial models that begin with the end goal of assumed known cash flows and ...
19
Intangibles and the Market Value of Biopharmaceutical Startups
... biopharmaceutical industry according to Filson et al. (2015). To measure the R&D output, most studies have used the number of patent applications a firm has filed, weighted by the number of citations ...
26
Using Registries to Identify Adverse Events in Rheumatic Diseases
... groups, biopharmaceutical industry repre- sentatives and other stakeholders, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and the Duke Clinical Re- search Institute (DCRI) have ...
13
Development of Glycerol Feedback Control, Cell Density Measurement Device, and Supervisory Control and Data Acquisition (SCADA) Software for Automation of High Cell Density Pichia pastoris Fermentations in a 30L Bioreactor.
... Pichia pastoris is one of the standard heterologous protein expression systems for the biopharmaceutical industry. Pilot-scale bioprocesses often lack inexpensive flexible system for [r] ...
106
THE BIOPHARMACEUTICAL CLASSIFICATION SYSTEM (BCS): PRESENT STATUS AND FUTURE PROSPECTIVES
... The Biopharmaceutical classification system (BCS) - a Brief Overview: The oral route of drug administration is the most preferable method for administering drugs for systemic ...
5
Formulation Development and Evaluation of Taste Masked Chewable Tablet of Sildenafil Citrate
... Rushiraj Jani et al., (2016) Sildenafil citrate is one of the most effective agents for treatment of erectile dysfunction which acts by inhibiting thecGMP-specific phosphodiesterase type 5. Extensive research work is ...
138
Physical-chemical properties and the reactivity of pyridoxine and pyrrolidone carboxylate and their protolytic forms
... Since biopharmaceutical and pharmacological properties of this drug depend on biochemical transfor- mation its components, of the aim of this work was to determine the structure of possible ionized pyridoxine and ...
9
Biopharmaceutical enterprises comparative research base on market oriented and bank oriented corporate governance models
... U.S. biopharmaceutical enterprises boards affiliate branches to undertake policy-making, and board composition varies according to different types of biopharmaceutical enterprises, ...U.S. ...
7
Novel formulation and biopharmaceutical challenges of oral cancer therapy
... Gastrointestinal transit route Toxicity Intestinal Membrane Dosage Form Drug in solution Intestinal Fluid Normal Organs Liver Portal Circulation Systemic Circulation Kidney Un-dissolved [r] ...
33
Biopharmaceutical insights of particulate emulsified systems - a prospective overview
... and biopharmaceutical properties of these liquid isotropic homogenous systems have gained substantive research ...and biopharmaceutical principles on absorption and disposition patterns of ME/NEs was ...
8
LIQUISOLID COMPACT TECHNOLOGY: A REVIEWG. Geethika*, Kameswara Rao. S, B. Ravindra Babu, K. Kumar Babu,M. Mamatha. Murali, V. BhagyarajuDOWNLOAD/VIEW
... Solubility of drugs is a major factor in the design ofpharmaceutical formulations lead to variable oralbioavailability. Dissolution is an important factor forabsorption of drugs especially in case of water insoluble ...
8
Quality Control of Widely Used Therapeutic Recombinant Proteins by a Novel Real-Time PCR Approac
... Background: Existence of bacterial host-cell DNA contamination in biopharmaceutical products is a potential risk factor for patients receiving these drugs. Hence, the quantity of contamination must be controlled ...
7